<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Natriuretic peptide measurement in heart failure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Natriuretic peptide measurement in heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Natriuretic peptide measurement in heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Horng H Chen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The natriuretic peptide system impacts salt and water handling and pressure regulation and may influence myocardial structure and function.</p><p>B-type natriuretic peptide (BNP) is a natriuretic hormone initially identified in the brain but released primarily from the heart, particularly the ventricles. Cleavage of the prohormone proBNP produces biologically active 32 amino acid BNP as well as biologically inert 76 amino acid N-terminal pro-BNP (NT-proBNP).</p><p>Atrial natriuretic peptide (ANP) is a hormone that is released from myocardial cells in the atria and in some cases the ventricles in response to volume expansion and possibly increased wall stress [<a href="#rid1">1</a>]. ANP circulates primarily as a 28 amino acid polypeptide, consisting of amino acids 99-126 from the C-terminal end of its prohormone, pro-ANP.</p><p>The release of both ANP and BNP is increased in heart failure (HF), as ventricular cells are recruited to secrete both ANP and BNP in response to the high ventricular filling pressures [<a href="#rid2">2</a>]. The plasma concentrations of both hormones are increased in patients with asymptomatic and symptomatic left ventricular (LV) dysfunction, permitting their use in diagnosis  (<a class="graphic graphic_figure graphicRef55557" href="/z/d/graphic/55557.html" rel="external">figure 1</a>).</p><p>The diagnostic and prognostic value of measuring plasma BNP, NT-proBNP and mid-regional pro-ANP (MR-proANP) in patients with HF will be presented here.</p><p>Natriuretic levels in non-HF settings are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17124.html" rel="external">"Natriuretic peptide measurement in non-heart failure settings"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHYSIOLOGIC ROLE IN HF</span><span class="headingEndMark"> — </span>Both atrial natriuretic peptide (ANP) and BNP have diuretic, natriuretic, and hypotensive effects. They also inhibit the renin-angiotensin system, endothelin secretion, and systemic and renal sympathetic activity  (<a class="graphic graphic_figure graphicRef64943" href="/z/d/graphic/64943.html" rel="external">figure 2</a>) [<a href="#rid3">3</a>]. Among patients with HF, increased secretion of ANP and BNP may partially counteract the effects of norepinephrine, endothelin, and angiotensin II, limiting the degree of vasoconstriction and sodium retention [<a href="#rid4">4,5</a>]. In one study of patients with moderately severe HF, for example, administration of an orally active inhibitor of the endopeptidase that degrades ANP led to reductions in plasma aldosterone concentrations and right ventricular (RV) and LV filling pressures, as well as a decrease in body weight presumed to be due to diuresis, natriuresis, or both [<a href="#rid4">4</a>]. These effects were presumably mediated by enhanced natriuretic peptide activity.</p><p>An unexpected finding is that BNP may protect against collagen accumulation and the pathologic remodeling that contributes to progressive HF. Studies in BNP knockout mice reveal increased cardiac fibrosis in response to ventricular pressure overload [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">"Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Remodeling'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ASSAY INTERPRETATION</span></p><p class="headingAnchor" id="H4"><span class="h2">Plasma BNP</span><span class="headingEndMark"> — </span>A variety of clinical immunoassays are clinically available for plasma BNP [<a href="#rid7">7</a>]. These include a rapid point-of-care assay [<a href="#rid8">8-11</a>] as well as central lab assays that offer improved precision compared to the point-of-care test. These assays are harmonized at a value of 100 ng/L, but above or below this level the correlations are not strong.</p><p>Plasma BNP concentrations have been variously reported in units of pmol/L, ng/L, or pg/mL. The currently available rapid assay reports results in pg/mL; the assay range is 5 to 1300 pg/mL [<a href="#rid11">11</a>] or 1.4 to 376 pmol/L [<a href="#rid9">9</a>].</p><p>Genetic factors may account for roughly 40 percent of the total variation in plasma BNP in normal subjects [<a href="#rid12">12</a>]. Similar variability has been noted with N-terminal pro-BNP (NT-proBNP) [<a href="#rid13">13</a>]. (See <a class="local">'N-terminal pro-BNP'</a> below.)</p><p>A potential source of error is that plasma BNP concentrations can vary with the assay used (due to various antibody configurations), age, sex, and body mass index [<a href="#rid14">14</a>]. The normal values tend to increase with age and to be higher in women than men.</p><p class="headingAnchor" id="H5"><span class="h2">Plasma N-terminal pro-BNP</span><span class="headingEndMark"> — </span>In normal subjects, the plasma concentrations of BNP and NT-proBNP are similar (approximately 10 pmol/L). However, in patients with LV dysfunction, plasma NT-proBNP rises more than BNP. Scaling varies among BNP assays while NT-proBNP assays are standardized, so there is no simple conversion factor to compare BNP and NT-proBNP levels. As discussed below, an NT-proBNP level &gt;900 pg/mL provides roughly equivalent accuracy as a BNP level of &gt;100 pg/mL for diagnosis of HF.</p><p>Plasma concentrations of NT-proBNP are higher in older individuals and in women than men [<a href="#rid13">13</a>]. On the other hand, plasma BNP and NT-proBNP are lower in obese individuals [<a href="#rid15">15</a>], indicating that optimal reference intervals should account for age, sex, and perhaps body mass index (or other measure of body composition). In addition, NT-proBNP increases with renal failure and optimal cut-off values for diagnosis in such patients have not been clearly established [<a href="#rid16">16</a>]. (See <a class="local">'Renal failure'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Assay purity</span><span class="headingEndMark"> — </span>Available commercial assays for plasma BNP or NT-proBNP actually measure mixtures of peptides. Plasma BNP assays appear to detect various degradation products of BNP as well as proBNP. Assays for NT-proBNP likely also detect proBNP. The relative contribution of individual natriuretic peptides has not yet been elucidated.</p><p class="headingAnchor" id="H9"><span class="h2">Variability</span><span class="headingEndMark"> — </span>Variability in peptide measurements must be considered when interpreting serial BNP or NT-proBNP results. Intraindividual biologic variation as well as analytic assay variation contribute to total variation [<a href="#rid17">17</a>]. Manual and point-of-care assays have greater analytic variation than central laboratory analyzers [<a href="#rid18">18</a>]. Total variability determines the percentage change (the relative change value or RCV) needed to demonstrate a significant difference in results over time. In a review of studies of BNP and NT-proBNP variability, a mean 25 percent decrease in BNP was required for a significant within day change and a mean 72 percent decline in BNP was required for a significant week to week change [<a href="#rid18">18</a>]. Variability for NT-proBNP testing was less, so RCVs were lower: an 11 percent decrease was required for a significant within day change and a 47 percent decrease was required for a significant week to week change.</p><p class="headingAnchor" id="H22201902"><span class="h2">Impact of conditions and medications</span></p><p class="headingAnchor" id="H22200902"><span class="h3">Renal failure</span><span class="headingEndMark"> — </span>Plasma BNP and NT-proBNP concentrations are elevated in patients with renal failure. In patients with chronic kidney disease, decreased estimated GFR is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations.</p><p>Plasma BNP concentrations are often elevated in patients with renal insufficiency, whether or not they have clinically diagnosed HF [<a href="#rid19">19-22</a>]. BNP is cleared by the receptor-mediated binding and removal, neutral endopeptidase [<a href="#rid19">19,20</a>], as well as by passive excretion so GFR is inversely related to BNP concentrations [<a href="#rid16">16,23</a>]. As a result, the cut-off values for plasma BNP in patients with renal insufficiency are different from those in patients with normal renal function. Elevations in BNP levels in renal failure may also result from volume expansion or from LV hypertrophy [<a href="#rid19">19</a>] and monitoring plasma BNP does not appear to facilitate the management of these patients [<a href="#rid21">21</a>].</p><p>We do not use plasma BNP or NT-proBNP for the diagnosis or management of HF in patients with renal failure, with or without dialysis. The main value would be a low plasma BNP, which would exclude LV dysfunction.</p><p>Measuring plasma NT-proBNP has an added problem since NT-proBNP is cleared by the kidney and its plasma concentration is elevated by renal failure alone. There are insufficient data to establish clear cut-off values for NT-proBNP in this setting. In a review of 599 patients with a serum creatinine ≤2.5 mg/dL (221 micromol/L) who presented to the Emergency Department with a complaint of dyspnea, cut-off values for patients with an estimated glomerular filtration rate (GFR) of ≥60 mL/min per 1.73 m<sup>2</sup> were &gt;450 pg/mL in those less than 50 years of age and &gt;900 pg/mL in older patients; the cutoff was 1200 pg/mL for patients with a GFR &lt;60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid16">16</a>]. Using these values, the sensitivity and specificity for diagnosing HF were 85 and 88 percent for those with a GFR ≥60 mL/min per 1.73 m<sup>2</sup> and 89 and 72 percent in those with a GFR &lt;60 mL/min per 1.73 m<sup>2</sup>.</p><p class="headingAnchor" id="H27939917"><span class="h3">Age, sex, and body mass</span><span class="headingEndMark"> — </span>Patients with obesity tend to have lower plasma BNP and NT-proBNP concentrations than nonobese patients [<a href="#rid15">15,24-27</a>]. There are conflicting data as to whether the lower values in patients with obesity reflect a direct association [<a href="#rid15">15</a>] or are a function of other variables including age, sex, and HF severity [<a href="#rid26">26</a>]. Despite the lower values in patients with obesity, higher plasma BNP values within any body mass index category are associated with worse outcomes [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3459057629"><span class="h3">Drug effects</span><span class="headingEndMark"> — </span>During treatment with the angiotensin receptor-neprilysin inhibitor <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>, plasma NT-proBNP levels but not plasma BNP levels can be used to guide therapy. BNP is degraded by neprilysin so ARNI causes elevation of BNP levels. Since NT-proBNP is not degraded by neprilysin, its levels are not increased by neprilysin inhibition. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H22201975"><span class="h3">Other conditions</span><span class="headingEndMark"> — </span>Natriuretic peptide levels are elevated in some patients with non-HF conditions such as coronary heart disease, valvular heart disease, pulmonary hypertension, and sepsis. The diagnostic and prognostic value of measuring plasma BNP and NT-proBNP in asymptomatic individuals and patients with non-HF conditions is discussed separately  (<a class="graphic graphic_table graphicRef99857" href="/z/d/graphic/99857.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/17124.html" rel="external">"Natriuretic peptide measurement in non-heart failure settings"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">PLASMA BNP IN HEART FAILURE</span><span class="headingEndMark"> — </span>The circulating concentration of BNP is less than 20 percent of that of atrial natriuretic peptide (ANP) in normal subjects, but can equal or exceed that of ANP in patients with HF; this wider range of concentrations makes measurement of BNP more useful than ANP in evaluation of patients with HF. For this reason, the clinical experience with plasma BNP is much greater than with plasma ANP [<a href="#rid28">28,29</a>]. The plasma half-life of BNP is estimated to be about 20 minutes [<a href="#rid30">30</a>]. However, as noted above, assays for BNP likely measure a mixture of BNP and proBNP.</p><p class="headingAnchor" id="H3612693290"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>The utility of BNP in differentiating cardiac and noncardiac causes of dyspnea in difficult to assess patients remains uncertain. Plasma BNP concentration may be useful in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>As a part of the clinical evaluation of patients presenting with dyspnea of uncertain etiology, including patients with a history of cardiomyopathy and HF who may have a noncardiac cause of dyspnea. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p>Most dyspneic patients with HF have values above 400 pg/mL, while values below 100 pg/mL have a very high negative predictive value for HF as a cause of dyspnea [<a href="#rid28">28</a>]. In the range between 100 and 400 pg/mL, plasma BNP concentrations are not very sensitive or specific for detecting or excluding HF. Other diagnoses, such as pulmonary embolism, LV dysfunction without exacerbation, and cor pulmonale should also be considered in patients with plasma BNP concentrations in this range.</p><p>Normal plasma BNP values increase with age and are higher in women than men [<a href="#rid14">14</a>]. Thus, somewhat higher cutoff values may be needed in these settings, although the optimal discriminatory values that should be used have not been determined.</p><p class="bulletIndent1"><span class="glyph">●</span>Possibly, to monitor patients with an established diagnosis of HF, especially those with moderate to severe HF. Such measurements can be made as an adjunct to outpatient follow-up office visits. A rise in plasma BNP above the patient's own baseline value should trigger closer assessment for a possible exacerbation of HF.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">BNP and the diagnosis of HF in the patient with dyspnea</span><span class="headingEndMark"> — </span>Establishing HF as a cause of dyspnea in patients presenting to the emergency department is extremely important, but symptoms and physical findings may not be sufficiently sensitive to make an accurate diagnosis. The assay for plasma BNP is a useful test in the evaluation of patients with dyspnea, and is especially useful as a component of the evaluation of suspected HF when the diagnosis is uncertain [<a href="#rid31">31-37</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Breathing Not Properly study</span><span class="headingEndMark"> — </span>The value of rapid bedside measurement of plasma BNP for distinguishing between HF and a pulmonary cause of dyspnea was best evaluated in the Breathing Not Properly (BNP) study of 1586 patients presenting to the emergency department or urgent care setting with a major complaint of acute dyspnea [<a href="#rid31">31</a>]. The final diagnosis was HF in 47 percent (confirmed by chest radiograph and/or echocardiography and other clinical tests by two independent cardiologists), no HF in 49 percent, and noncardiac dyspnea in patients with a past history of LV dysfunction in 5 percent. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma BNP was markedly higher in patients with clinically diagnosed HF (including patients with right HF due to cor pulmonale) compared to those without HF (mean 675 versus 110 pg/mL). Intermediate values were found in patients with baseline LV dysfunction without an acute exacerbation (346 pg/mL)  (<a class="graphic graphic_figure graphicRef82685" href="/z/d/graphic/82685.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A plasma BNP &gt;100 pg/mL diagnosed HF with a sensitivity, specificity, and predictive accuracy of 90, 76, and 83 percent, respectively. Choosing values &gt;125 or &gt;150 pg/mL decreased sensitivity, increased specificity, and did not change overall predictive accuracy. The predictive accuracy of plasma BNP for HF was equivalent to or better than other parameters such as cardiomegaly on chest x-ray, a history of HF, or rales on physical examination, and was better than the widely used NHANES and Framingham criteria for the diagnosis of HF (83 versus 67 and 73 percent, respectively). (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p></p><p>A subsequent analysis showed that atrial fibrillation (AF), which was present in 292 patients, was associated with higher BNP levels in the patients who did not have a final diagnosis of HF (119 versus 25 pg/mL in patients without AF) [<a href="#rid38">38</a>]. As a result, a BNP cutoff of ≥100 pg/mL was associated with a specificity of only 40 percent compared to 79 percent in patients without AF. Using a cutoff of ≥200 pg/mL in patients with AF increased specificity from 40 to 73 percent with a smaller reduction in sensitivity from 95 to 85 percent.</p><p class="bulletIndent1"><span class="glyph">●</span>The plasma concentration of BNP correlated with NYHA functional class, ranging from 244 to 817 pg/mL for class I to IV.</p><p></p><p>Another report from the BNP study compared plasma BNP to initial clinical judgment [<a href="#rid32">32</a>]. Among patients judged clinically to have a ≥80 percent probability of HF, a plasma BNP &gt;100 pg/mL was more sensitive (90 versus 49 percent) but less specific (73 versus 96 percent) than clinical judgment [<a href="#rid32">32</a>]. Adding BNP to clinical judgment increased diagnostic accuracy (HF versus no HF) from 74 to 81 percent. Among patients with a 21 to 79 percent clinical probability of HF, a plasma BNP &gt;100 pg/mL had a diagnostic accuracy of 74 percent and only misclassified 7 percent of patients who had HF. Among patients originally thought to have less than a 21 percent clinical probability of HF, 17 percent had a final diagnosis of HF and plasma BNP correctly diagnosed 90 percent of these patients.</p><p class="headingAnchor" id="H13"><span class="h3">Heart failure with preserved ejection fraction</span><span class="headingEndMark"> — </span>Elevations in plasma BNP can establish the presence of HF with preserved ejection fraction (HFpEF) with similar accuracy to HF with reduced ejection fraction (HFrEF), though values are generally higher with HFrEF [<a href="#rid34">34,39,40</a>]. However, the values do not adequately differentiate between HFrEF and HFpEF [<a href="#rid34">34,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Impact on outcomes and costs</span><span class="headingEndMark"> — </span>Studies evaluating the impact on health outcomes and health services utilization of BNP measurement for evaluation of dyspnea have reported conflicting results which may be due to differences in patient populations and/or health systems (eg, high clinical diagnostic accuracy without BNP testing may be associated with less benefit with BNP testing).</p><p class="headingAnchor" id="H19"><span class="h2">Prognosis of HF</span><span class="headingEndMark"> — </span>Plasma BNP levels are predictors of outcome in both acute and chronic HF.</p><p class="headingAnchor" id="H20"><span class="h3">Chronic HF</span><span class="headingEndMark"> — </span>Plasma BNP provides prognostic information in patients with chronic HF [<a href="#rid41">41-45</a>], and those with asymptomatic or minimally symptomatic LV dysfunction [<a href="#rid46">46-49</a>].</p><p>A systematic review analyzed 19 studies in which plasma BNP was used to estimate the relative risk of death or cardiovascular events in patients with HF [<a href="#rid50">50</a>]. Every 100 pg/mL increase in plasma BNP was associated with a 35 percent increase in the relative risk of death. In multivariable models, plasma BNP was a strong indicator of risk and may be a better predictor of survival than traditional risk factors such as NYHA class and possibly LV ejection fraction.</p><p>In an analysis of more than 4000 patients from the Val-HeFT trial, those with a baseline plasma BNP concentration in the highest quartile (≥238 pg/mL) had a significantly greater mortality at two years than those with a plasma BNP in the lowest quartile (&lt;41 pg/mL) (32.4 versus 9.7 percent)  (<a class="graphic graphic_figure graphicRef78693" href="/z/d/graphic/78693.html" rel="external">figure 4</a>) [<a href="#rid42">42</a>].</p><p>Similarly, persistent elevation of plasma BNP despite optimal medical therapy also has prognostic significance [<a href="#rid45">45,46,48,51,52</a>]. In one series of 85 chronic HF patients, a plasma BNP below 73 pg/mL was associated with markedly and significantly higher survival compared to those with higher values  (<a class="graphic graphic_figure graphicRef66458" href="/z/d/graphic/66458.html" rel="external">figure 5</a>) [<a href="#rid48">48</a>]. In another series of 102 patients with class III and IV HF, a plasma BNP concentration persistently above 240 pg/mL after treatment had a sensitivity and specificity of 73 and 74 percent for mortality at follow-up of more than two years [<a href="#rid46">46</a>]. In hospitalized patients, persistent elevation of plasma BNP prior to discharge from the hospital is predictive of death or readmission [<a href="#rid52">52</a>].</p><p>As mentioned above, plasma BNP and N-terminal pro-BNP concentrations tend to be lower in obese and overweight patients [<a href="#rid15">15,24-27</a>]. Despite the relatively lower values, plasma BNP retains its prognostic value in such patients with advanced HF [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Acute decompensated HF</span><span class="headingEndMark"> — </span>The relationship between admission plasma BNP levels and the risk of in-hospital mortality for patients with acute decompensated HF was assessed in the ADHERE registry [<a href="#rid53">53</a>]. Admission BNP levels were available in 19,544 patients with HF due to systolic dysfunction and in 18,164 HF patients with preserved LV function. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>BNP values were categorized according to quartiles. Quartiles 1 to 4: &lt;430, 430 to 839, 840 to 1729, and ≥1739 pg/mL respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was a nearly linear relationship between BNP quartiles and in-hospital mortality. Quartiles 1 to 4: 1.9, 2.8, 3.8, and 6 percent respectively.</p><p></p><p class="headingAnchor" id="H22"><span class="h2">Screening for LV dysfunction</span><span class="headingEndMark"> — </span>Plasma BNP has been evaluated as a screening test for asymptomatic LV dysfunction, with the goal being early identification so that therapy can be given to slow the progression to overt HF. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3490.html" rel="external">"Approach to diagnosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Major society recommendations</span><span class="headingEndMark"> — </span>We agree with the following recommendations from the 2017 American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) focused guideline update:</p><p class="bulletIndent1"><span class="glyph">●</span>To measure natriuretic peptide biomarkers in patients presenting with dyspnea, to support a diagnosis of HF [<a href="#rid54">54</a>]. These measurements are to be viewed as part of the total evaluation but should not be used in isolation to confirm or exclude the presence of HF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To measure natriuretic peptide biomarkers for establishing prognosis in patients with chronic HF, and on admission to the hospital to establish prognosis in acutely decompensated HF. The measurement of a natriuretic peptide biomarker predischarge to establish prognosis may also be of value.</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Limitations</span><span class="headingEndMark"> — </span>There are several important limitations to the use of plasma BNP for diagnosis and follow-up of HF [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients may present with more than one cause of dyspnea (such as pneumonia and an exacerbation of HF). Thus, a high plasma BNP concentration does not exclude the presence of other diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients with acute decompensated HF, plasma BNP levels are not diagnostic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with severe chronic HF may have persistently elevated plasma BNP concentrations regardless of treatment, and such levels may not be useful in guiding management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Right HF and pulmonary hypertension are associated with elevations in plasma BNP (see  <a class="medical medical_review" href="/z/d/html/17124.html" rel="external">"Natriuretic peptide measurement in non-heart failure settings", section on 'Pulmonary hypertension'</a>). However, when right HF is due solely to lung disease and not due to secondary pulmonary hypertension from left sided heart disease or as part of a global cardiomyopathy, elevated plasma BNP may be misinterpreted since dyspnea in these patients is due to lung disease not left HF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma BNP measurements alone are not sufficient to guide therapeutic decision-making in patients with HF. They should be used as an adjunct to, and not a substitute for, clinical assessment. As an example, failure of plasma BNP to change significantly should not be interpreted as conclusive evidence that the new therapy was of no benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma BNP cannot be used for clinical assessment in patients being treated with <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> or <a class="drug drug_general" data-topicid="10128" href="/z/d/drug information/10128.html" rel="external">nesiritide</a>; in comparison, N-terminal pro-BNP can be used. (See <a class="local">'Drug effects'</a> above.)</p><p></p><p>Not all patients with symptomatic HF have high plasma BNP concentrations and not all asymptomatic patients have low values. This was demonstrated in a review of 558 consecutive ambulatory patients with treated stable HF in a specialized outpatient HF clinic [<a href="#rid55">55</a>]. The following observations were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Among the 449 symptomatic patients, 106 (24 percent) had plasma BNP &lt;100 pg/mL. These patients were more likely to be young and female and to have a nonischemic cardiomyopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, elevated plasma BNP was seen in some of the 109 asymptomatic patients. Although the mean plasma BNP in this group was 87 pg/mL, values as high as 572 pg/mL were seen.</p><p></p><p>These findings illustrate the importance of the range of individual patient variation, as with any diagnostic test. The use of serial serum BNP concentrations to monitor the clinical course of a patient provides a more reliable guide to management than can be obtained from a single measurement.</p><p class="headingAnchor" id="H35"><span class="h1">N-TERMINAL PRO-BNP</span><span class="headingEndMark"> — </span>Like atrial natriuretic peptide (ANP), BNP is cleaved from the C-terminal end of its prohormone, pro-BNP. The N-terminal fragment, N-terminal pro-BNP (NT-proBNP), is also released into the circulation. NT-proBNP has a longer plasma half-life than BNP (approximately 25 to 70 versus 20 minutes) [<a href="#rid30">30</a>]. However, as noted above, assays for NT-proBNP likely measure a mixture of NT-proBNP and proBNP. Issues related to the NT-proBNP assay are discussed above. (See <a class="local">'Assay interpretation'</a> above.)</p><p>Measurement of NT-proBNP, like measurement of plasma BNP, has diagnostic and prognostic value in HF and other cardiovascular diseases.</p><p class="headingAnchor" id="H36"><span class="h2">Role in HF</span><span class="headingEndMark"> — </span>The accuracy of diagnosis of HF in both primary care and emergency department settings can be improved with NT-proBNP measurement. The following observations illustrate the utility of NT-proBNP primarily in patients with systolic HF; preliminary data suggest it is also useful in HF due to diastolic dysfunction as is plasma BNP [<a href="#rid56">56</a>]. (See <a class="local">'Heart failure with preserved ejection fraction'</a> above.)</p><p class="headingAnchor" id="H37"><span class="h3">Acute decompensated HF</span><span class="headingEndMark"> — </span>Like BNP, NT-proBNP has been found to be useful in the evaluation of a patient presenting with dyspnea in the acute setting [<a href="#rid31">31,32,57-61</a>]. This is best illustrated by a retrospective cohort study that combined and analyzed data from three previous prospective studies [<a href="#rid57">57</a>]. Differences in plasma NT-proBNP among 1256 patients with and without acute HF were compared, and the relationship between plasma NT-proBNP and symptoms was examined. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The optimal value for distinguishing HF from other causes of dyspnea varied with patient age. For patients &lt;50, 50 to 75, and &gt;75 years of age, the optimal plasma NT-proBNP cutoffs for diagnosing HF were 450 pg/mL, 900 pg/mL, and 1800 pg/mL respectively. Overall, these cutoffs yielded a sensitivity and specificity of 90 and 84 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Across the entire population, NT-proBNP levels below 300 pg/mL were optimal for excluding a diagnosis of HF, with a negative predictive value of 98 percent.</p><p></p><p>The concentration of NT-proBNP is elevated in the pleural fluid in patients with HF and a pleural effusion and may therefore be of some value in the diagnosis of pleural effusion. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'N-terminal pro-BNP'</a>.)</p><p class="headingAnchor" id="H40"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Plasma NT-proBNP correlates with prognosis in patients with acute and chronic HF [<a href="#rid47">47,61-65</a>]. In a subgroup of 1011 patients in the COPERNICUS study, the median baseline NT-proBNP concentration was 1767 pg/mL [<a href="#rid62">62</a>]. All-cause mortality at one year was significantly higher for patients with a plasma NT-proBNP above the median, compared to levels below the median (22 versus 7 percent, risk ratio 2.7). A similar increase was found in the combined end point of all-cause mortality or hospitalization for HF (38 versus 19 percent, risk ratio 2.4). Similar observations were made in the Australia/New Zealand Heart Failure trial [<a href="#rid47">47,63</a>].</p><p class="headingAnchor" id="H41"><span class="h3">Primary care setting</span><span class="headingEndMark"> — </span>The value of NT-proBNP in the primary care setting was demonstrated in a study of 305 patients presenting to their general practitioner with symptoms of HF who were initially evaluated and then randomly assigned to a second diagnostic evaluation with or without knowledge of the result [<a href="#rid66">66</a>]. Final diagnoses were made by an expert panel. Diagnostic accuracy (either correct identification or exclusion of HF) improved from 52 to 60 percent without NT-proBNP (8 percent change) but from 49 to 70 percent with NT-proBNP (21 percent change).</p><p class="headingAnchor" id="H42"><span class="h2">Role in cardiomyopathy</span><span class="headingEndMark"> — </span>NT-proBNP predicts cardiac involvement and prognosis in patients with AL amyloidosis [<a href="#rid67">67</a>] and may be a useful screen for LV dysfunction due to late cardiotoxicity in children who have received anthracycline chemotherapy [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H47"><span class="h1">COMPARISON OF PLASMA BNP AND N-TERMINAL PRO-BNP</span><span class="headingEndMark"> — </span>Limited data are available comparing the diagnostic and prognostic values of plasma BNP and N-terminal pro-BNP (NT-proBNP). As noted above, there is no universal conversion factor to compare BNP and NT-proBNP levels. An NT-proBNP level &gt;900 pg/mL provides roughly equivalent accuracy as a BNP level of &gt;100 pg/mL for diagnosis of HF.</p><p>A study of 164 patients hospitalized with decompensated HF found that admission and discharge NT-proBNP and BNP levels predicted cardiac mortality and all-cause mortality at 90 day follow-up [<a href="#rid69">69</a>]. NT-proBNP had greater prognostic value than BNP levels for all-cause mortality.</p><p>As alluded to above, greater increases in NT-proBNP than BNP levels are observed in renal failure. (See <a class="local">'Renal failure'</a> above.) It has been postulated that the diagnostic value of NT-proBNP may be in part be due to its sensitivity to renal dysfunction.</p><p class="headingAnchor" id="H27657875"><span class="h1">BNP OR NT-proBNP AS GUIDE TO THERAPY OF HF</span><span class="headingEndMark"> — </span>The plasma concentrations of BNP and N-terminal pro-BNP (NT-proBNP) fall after effective chronic treatment of HF, which suggests that measurement of plasma BNP may be helpful in titrating therapy [<a href="#rid41">41,46,70-73</a>]. The utility of serial BNP measurements to monitor the response to acute HF therapies is currently being investigated.</p><p class="headingAnchor" id="H1921753968"><span class="h2">Acute HF</span><span class="headingEndMark"> — </span>Natriuretic peptide levels have prognostic value in patients with acute HF but the available evidence does not support targeting lower levels as a means of improving outcomes in this setting. Since natriuretic peptides have relatively short half-lives, it has been postulated that serial measurements may help guide management of acute HF [<a href="#rid74">74</a>]. A systematic review including one randomized trial, three quasi-experimental studies, and 40 observational studies found low-quality evidence supporting an association between achievement of natriuretic predischarge thresholds (eg, BNP ≤250 pg/mL or NT-proBNP decline of at least 30 percent) and reduced acute HF mortality and readmission [<a href="#rid75">75</a>]. However, the BOT-AcuteHF randomized controlled trial (and the PRIMA II trial that has been presented but not yet published) studying the effect of treating to a target natriuretic peptide level found no improvement in outcomes with a natriuretic peptide-guided strategy, although patients who achieved the natriuretic peptide target had better outcomes than those who failed to achieve the target [<a href="#rid76">76,77</a>]. One possible explanation for the failure of a natriuretic peptide-guided strategy to improve outcomes is that natriuretic targets are not achievable in some patients given the limitations of current therapies [<a href="#rid77">77</a>].</p><p>A separate issue is that some patients with acute HF do not have elevated BNP or NT proBNP levels; natriuretic peptide levels may be mildly or not significantly elevated if the etiology of the HF is inflow tract obstruction (eg, mitral stenosis) [<a href="#rid78">78,79</a>], constrictive pericarditis [<a href="#rid80">80,81</a>], or if the HF is very acute (first hour or so) [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p class="headingAnchor" id="H27657882"><span class="h2">Chronic HF</span><span class="headingEndMark"> — </span>Randomized trials studying the effect of BNP- or NT-proBNP guided therapy on clinical outcomes have shown mixed results, although the weight of the evidence suggests modest or no clinical benefit from use of natriuretic peptide levels to aid optimization of HF drug doses. Although earlier trials found improved outcomes, the largest randomized trial (in which medical therapy was intensified similarly with or without natriuretic peptide level guidance) found no benefit.</p><p>A meta-analysis included 11 randomized trials (nine which provided individual patient data and two studies which provided aggregate data) comparing natriuretic peptide-guided treatment with usual care [<a href="#rid85">85</a>]. All-cause mortality was significantly reduced by natriuretic peptide-guided care (hazard ratio [HR] 0.62; 95% CI 0.45-0.86) based on individual patient data from 2000 patients. With the addition of aggregate data from two additional studies (with 431 patients), the reduction in mortality rate was borderline significant (HR 0.82; 95% CI 0.67-1.00, p = 0.045). Hospitalization due to HF (HR 0.80; 95% CI 0.67–0.94) was lower in natriuretic peptide-guided patients based on individual patient data from 2151 patients. Increasing doses of guideline directed medical therapy (angiotensin converting enzyme [ACE] inhibitor/angiotensin II receptor blocker [ARB], beta blocker, and mineralocorticoid receptor antagonist) were associated with reduced all-cause mortality. At study end, there was a higher percentage of patients receiving target ACE inhibitor/ARB doses in the natriuretic peptide guided group compared to the clinically guided group.</p><p>Despite the promising results of this meta-analysis, the subsequent GUIDE-IT trial (the largest randomized trial evaluating this strategy to date) found that NT-proBNP–guided therapy was not more effective than usual in improving outcomes in high-risk patients with HFrEF when managed by HF specialists at multiple high level medical centers [<a href="#rid86">86</a>]. This study assigned 894 patients with HFrEF (ejection fraction ≤40 percent), elevated natriuretic peptide levels within the prior 30 days, and a history of a prior HF event (HF hospitalization or equivalent) to either an NT-proBNP-guided strategy or usual care. The trial was stopped for futility when 894 of the planned 1100 patients had been enrolled with follow-up for a median of 15 months. The primary end point, composite of time-to-first HF hospitalization or cardiovascular mortality occurred in 164 patients (37 percent) in the NT-proBNP guided group and 164 patients (37 percent) in the usual care group (adjusted HR 0.98; 95% CI 0.79-1.22). Cardiovascular mortality was 12 percent in the NT-proBNP guided group and 13 percent in the usual care group (HR 0.94; 95% CI 0.65-1.37). None of the secondary end points nor the decreases in the NT-proBNP levels achieved differed significantly between groups. There were modest increases in HF drug doses in both groups.</p><p>However, the plasma BNP concentration may predict the likelihood of response to therapeutic intervention. In the Australia-New Zealand Heart Failure study, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a> appeared to reduce mortality only in patients with supramedian baseline values of BNP [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H27657889"><span class="h3">Exercise training</span><span class="headingEndMark"> — </span>Exercise training programs are recommended in patients with chronic HF. (See  <a class="medical medical_review" href="/z/d/html/3472.html" rel="external">"Cardiac rehabilitation in patients with heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3472.html" rel="external">"Cardiac rehabilitation in patients with heart failure", section on 'Evidence on effects of exercise'</a>.)</p><p>The effect of exercise training on natriuretic peptide levels was evaluated in a series of 95 patients randomly assigned to either exercise training or standard therapy for nine months [<a href="#rid87">87</a>]. In addition to a number of clinical improvements, patients assigned to exercise training had a decline in both BNP and NT-proBNP of approximately 30 percent, compared to no change in patients assigned to standard therapy.</p><p class="headingAnchor" id="H48"><span class="h1">ATRIAL NATRIURETIC PEPTIDE</span><span class="headingEndMark"> — </span>Atrial natriuretic peptide (ANP) is primarily released from the atria in response to volume expansion, apparently sensed as atrial stretch. ANP levels are increased in HF and correlate more closely with atrial volume than atrial pressure [<a href="#rid88">88</a>]. The prohormone of ANP (proANP) is a polypeptide of 126 amino acids. The N-terminal portion of proANP, termed proANP1–98 or N-terminal pro-ANP (NT-proANP), has a much longer half-life than mature ANP and has therefore been proposed as a more reliable analyte for measurement than ANP. An investigational commercial assay detects mid-regional pro-atrial natriuretic peptide (MR-proANP).</p><p>The multicenter BACH (Biomarkers in Acute Congestive Heart Failure) trial evaluated the utility of monitoring MR-proANP as compared to BNP in 1641 patients presenting to the emergency department with shortness of breath [<a href="#rid89">89</a>]. MR-proANP (≥120 pmol/l) was noninferior to BNP (≥100 pg/ml) for the diagnosis of AHF (sensitivity 97 versus 95.6 percent; specificity 59.9 versus 61.9 percent). MR-proANP provided additional discriminant value to BNP in patients with intermediate BNP (or NT-proBNP levels) or patients with obesity but not in those with renal insufficiency, age &gt;70 y, or edema.</p><p>The GISSI-HF trial provided evidence that measurement of MR-proANP provided prognostic information independent of NT-proBNP [<a href="#rid90">90</a>]. Natriuretic peptides and other vasoactive peptides were measured in 1237 patients with chronic stable HF at randomization and at three months. The addition of MR-proANP improved classification for mortality when added to models based on clinical risk factors alone (net reclassification improvement [NRI] = 0.12) or together with NT-proBNP (NRI =0.06). Increases in MRproANP levels were associated with mortality (HR 1.38, 95% CI 0.99–1.93 and HR 1.58, 95% CI 1.13–2.21 in the middle and highest versus lowest tertiles).</p><p>More data are needed to define the clinical utility of MR-proANP measurements.</p><p class="headingAnchor" id="H3903547104"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H1203669"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparing BNP and NT-pro-BNP values</strong> – In normal subjects, the plasma concentrations of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are similar (approximately 10 pmol/L). However, in patients with left ventricular (LV) dysfunction, plasma NT-proBNP rises more than BNP, with NT-proBNP concentrations approximately four-fold higher than BNP concentrations. (See <a class="local">'Plasma N-terminal pro-BNP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that influence interpretation</strong> – Factors that influence the interpretation of natriuretic peptide levels include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease</strong> – In patients with chronic kidney disease, decreased glomerular filtration rate (GFR) is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations, since NT-proBNP is cleared by the kidney. (See <a class="local">'Renal failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age, sex, and body mass</strong> – The normal values tend to increase with age and to be higher in women than men and lower in obese individuals. (See <a class="local">'Age, sex, and body mass'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assay variability</strong> – Plasma BNP and NT-proBNP concentrations vary with the assay used. Variability in peptide measurements must be considered when interpreting serial BNP or NT-proBNP results. (See <a class="local">'Variability'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of dyspnea</strong> – Plasma BNP or NT-proBNP is useful as a component of the evaluation of suspected heart failure (HF) when the diagnosis is uncertain  (<a class="graphic graphic_figure graphicRef82685" href="/z/d/graphic/82685.html" rel="external">figure 3</a>). (See <a class="local">'BNP and the diagnosis of HF in the patient with dyspnea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most dyspneic patients with HF have plasma BNP values above 400 pg/mL, while values below 100 pg/mL have a very high negative predictive value for HF as a cause of dyspnea. In the range between 100 and 400 pg/mL, plasma BNP concentrations are not very sensitive or specific for detecting or excluding HF. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients &lt;50, 50 to 75, and &gt;75 years of age, the optimal plasma NT-proBNP cutoffs for diagnosing HF were 450 pg/mL, 900 pg/mL, and 1800 pg/mL respectively. (See <a class="local">'Acute decompensated HF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevation in patients with HFpEF</strong> – Elevations in plasma BNP can establish the presence of HF due to diastolic dysfunction with similar accuracy to systolic dysfunction. However, the values do not differentiate between systolic and diastolic dysfunction. (See <a class="local">'Heart failure with preserved ejection fraction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management guided by routine use of BNP values</strong> – Randomized trials studying the effect of BNP- or NT-proBNP-guided therapy for patients with chronic HF on clinical outcomes have shown mixed results, although the weight of the evidence suggests there is modest or no clinical benefit when natriuretic peptide levels are used to guide optimization of HF drug therapy. (See <a class="local">'Chronic HF'</a> above and <a class="local">'Acute HF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic value</strong> – Plasma BNP and NT-proBNP provide prognostic information in patients with acute and chronic HF, and plasma BNP has prognostic value in those with asymptomatic or minimally symptomatic LV dysfunction  (<a class="graphic graphic_figure graphicRef78693" href="/z/d/graphic/78693.html" rel="external">figure 4</a> and <a class="graphic graphic_figure graphicRef66458" href="/z/d/graphic/66458.html" rel="external">figure 5</a>). (See <a class="local">'Prognosis of HF'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial natriuretic peptides</strong> – Mid-regional pro-atrial natriuretic peptide (MR-proANP) appears to be noninferior to BNP for diagnosis of acute HF and to have prognostic value in patients with chronic HF. (See <a class="local">'Atrial natriuretic peptide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in non-heart failure settings</strong> – Natriuretic peptide levels are elevated in some patients without clinical evidence of HF. The potential value of natriuretic peptide measurement in patients with coronary heart disease, valve disease, constrictive pericarditis, pulmonary hypertension, and sepsis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17124.html" rel="external">"Natriuretic peptide measurement in non-heart failure settings"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47:742.</a></li><li><a class="nounderline abstract_t">Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132:1961.</a></li><li><a class="nounderline abstract_t">Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001; 37:1221.</a></li><li><a class="nounderline abstract_t">Elsner D, Müntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70:494.</a></li><li><a class="nounderline abstract_t">Wilkins MR, Unwin RJ, Kenny AJ. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993; 43:273.</a></li><li><a class="nounderline abstract_t">Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97:4239.</a></li><li><a class="nounderline abstract_t">Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824.</a></li><li><a class="nounderline abstract_t">Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46:1529.</a></li><li><a class="nounderline abstract_t">Tjeerdsma G, de Boer RA, Boomsma F, et al. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2002; 86:143.</a></li><li><a class="nounderline abstract_t">Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144:834.</a></li><li class="breakAll">Product information available at www.biosite.com/products/triage.aspx (Accessed 3/7/05).</li><li><a class="nounderline abstract_t">Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003; 108:13.</a></li><li><a class="nounderline abstract_t">Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89:745.</a></li><li><a class="nounderline abstract_t">Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40:976.</a></li><li><a class="nounderline abstract_t">Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112:2163.</a></li><li><a class="nounderline abstract_t">Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47:91.</a></li><li><a class="nounderline abstract_t">Clerico A, Carlo Zucchelli G, Pilo A, et al. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006; 44:366.</a></li><li><a class="nounderline abstract_t">Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006; 152:828.</a></li><li><a class="nounderline abstract_t">Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76:1111.</a></li><li><a class="nounderline abstract_t">McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571.</a></li><li><a class="nounderline abstract_t">Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 2005; 67:278.</a></li><li><a class="nounderline abstract_t">Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44:420.</a></li><li><a class="nounderline abstract_t">Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47:52.</a></li><li><a class="nounderline abstract_t">Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590.</a></li><li><a class="nounderline abstract_t">Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594.</a></li><li><a class="nounderline abstract_t">McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004; 164:2247.</a></li><li><a class="nounderline abstract_t">Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47:85.</a></li><li><a class="nounderline abstract_t">Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 2002; 105:2328.</a></li><li><a class="nounderline abstract_t">de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316.</a></li><li><a class="nounderline abstract_t">Mair J. Biochemistry of B-type natriuretic peptide--where are we now? Clin Chem Lab Med 2008; 46:1507.</a></li><li><a class="nounderline abstract_t">Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161.</a></li><li><a class="nounderline abstract_t">McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416.</a></li><li><a class="nounderline abstract_t">McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9.</a></li><li><a class="nounderline abstract_t">Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367.</a></li><li><a class="nounderline abstract_t">Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349.</a></li><li><a class="nounderline abstract_t">Knudsen CW, Omland T, Clopton P, et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116:363.</a></li><li><a class="nounderline abstract_t">Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 2004; 44:740.</a></li><li><a class="nounderline abstract_t">Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005; 46:838.</a></li><li><a class="nounderline abstract_t">Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274.</a></li><li><a class="nounderline abstract_t">Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105:595.</a></li><li><a class="nounderline abstract_t">Stanek B, Frey B, Hülsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38:436.</a></li><li><a class="nounderline abstract_t">Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.</a></li><li><a class="nounderline abstract_t">de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584.</a></li><li><a class="nounderline abstract_t">Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934.</a></li><li><a class="nounderline abstract_t">Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392.</a></li><li><a class="nounderline abstract_t">Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.</a></li><li><a class="nounderline abstract_t">Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999; 99:786.</a></li><li><a class="nounderline abstract_t">Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509.</a></li><li><a class="nounderline abstract_t">Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20:1799.</a></li><li><a class="nounderline abstract_t">Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.</a></li><li><a class="nounderline abstract_t">Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386.</a></li><li><a class="nounderline abstract_t">Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43:635.</a></li><li><a class="nounderline abstract_t">Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49:1943.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70:776.</a></li><li><a class="nounderline abstract_t">Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108:2964.</a></li><li><a class="nounderline abstract_t">Tschöpe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26:2277.</a></li><li><a class="nounderline abstract_t">Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27:330.</a></li><li><a class="nounderline abstract_t">Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948.</a></li><li><a class="nounderline abstract_t">Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6:301.</a></li><li><a class="nounderline abstract_t">Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728.</a></li><li><a class="nounderline abstract_t">Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006; 27:839.</a></li><li><a class="nounderline abstract_t">Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110:1780.</a></li><li><a class="nounderline abstract_t">Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37:1781.</a></li><li><a class="nounderline abstract_t">Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168.</a></li><li><a class="nounderline abstract_t">Schou M, Gustafsson F, Corell P, et al. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J 2007; 154:123.</a></li><li><a class="nounderline abstract_t">Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42:1793.</a></li><li><a class="nounderline abstract_t">Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440.</a></li><li><a class="nounderline abstract_t">Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21:2349.</a></li><li><a class="nounderline abstract_t">Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008; 51:1874.</a></li><li><a class="nounderline abstract_t">Yoshimura M, Mizuno Y, Nakayama M, et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002; 112:716.</a></li><li><a class="nounderline abstract_t">Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126.</a></li><li><a class="nounderline abstract_t">Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454.</a></li><li><a class="nounderline abstract_t">Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733.</a></li><li><a class="nounderline abstract_t">Bhardwaj A, Januzzi JL Jr. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol 2009; 8:146.</a></li><li><a class="nounderline abstract_t">McQuade CN, Mizus M, Wald JW, et al. Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure: A Systematic Review. Ann Intern Med 2017; 166:180.</a></li><li><a class="nounderline abstract_t">Carubelli V, Lombardi C, Lazzarini V, et al. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:828.</a></li><li><a class="nounderline abstract_t">Felker GM, Whellan DJ. Inpatient Management of Heart Failure: Are We Shooting at the Right Target? Ann Intern Med 2017; 166:223.</a></li><li><a class="nounderline abstract_t">Leszek P, Klisiewicz A, Janas J, et al. Determinants of the reduction in B-type natriuretic peptide after mitral valve replacement in patients with rheumatic mitral stenosis. Clin Physiol Funct Imaging 2010; 30:473.</a></li><li><a class="nounderline abstract_t">Sharma V, Stewart RA, Zeng I, et al. Comparison of atrial and brain natriuretic peptide for the assessment of mitral stenosis. Heart Lung Circ 2011; 20:517.</a></li><li><a class="nounderline abstract_t">Parakh N, Mehrotra S, Seth S, et al. NT pro B type natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. Indian Heart J 2015; 67:40.</a></li><li><a class="nounderline abstract_t">Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005; 45:1900.</a></li><li><a class="nounderline abstract_t">Omar HR, Guglin M. Acute systolic heart failure with normal admission BNP: clinical features and outcomes. Int J Cardiol 2017; 232:324.</a></li><li><a class="nounderline abstract_t">Omar HR, Guglin M. A single BNP measurement in acute heart failure does not reflect the degree of congestion. J Crit Care 2016; 33:262.</a></li><li><a class="nounderline abstract_t">Brentana L, Temporelli PL, Corrà U, et al. Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case? Int J Cardiol 2007; 122:e18.</a></li><li><a class="nounderline abstract_t">Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014; 35:1559.</a></li><li><a class="nounderline abstract_t">Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2017; 318:713.</a></li><li><a class="nounderline abstract_t">Passino C, Severino S, Poletti R, et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 2006; 47:1835.</a></li><li><a class="nounderline abstract_t">Globits S, Frank H, Pacher B, et al. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J 1998; 135:592.</a></li><li><a class="nounderline abstract_t">Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55:2062.</a></li><li><a class="nounderline abstract_t">Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010; 12:338.</a></li></ol></div><div id="topicVersionRevision">Topic 3486 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487838" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477647" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300426" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386491" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441223" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737768" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiac fibrosis in mice lacking brain natriuretic peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18760965" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : State of the art: using natriuretic peptide levels in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017928" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419550" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422152" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422152" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821537" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Heritability and genetic linkage of plasma natriuretic peptide levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807847" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225726" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plasma brain natriuretic peptide concentration: impact of age and gender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16203929" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386670" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16599827" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17070141" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702899" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612980" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610252" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332214" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386664" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120816" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Obesity and suppressed B-type natriuretic peptide levels in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769680" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of obesity on plasma natriuretic peptide levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534162" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relationship between obesity and B-type natriuretic peptide levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386669" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : B-type natriuretic peptide levels in obese patients with advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021215" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892964" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : B-type natriuretic peptide in cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842106" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Biochemistry of B-type natriuretic peptide--where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124404" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135939" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9433422" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biochemical detection of left-ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231433" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9365448" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006584" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15312852" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139134" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566457" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11827925" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11499735" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628948" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15120815" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738297" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021226" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079662" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244219" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10581138" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774989" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216951" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975475" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498579" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461007" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662703" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014646" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16293638" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820160" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14987580" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932611" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510467" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381643" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401111" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451800" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584564" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14642690" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719281" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805337" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466803" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pro-B-type natriuretic peptide levels in acute decompensated heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12079712" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791374" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417542" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17448376" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952548" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27894126" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27322401" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27894128" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Inpatient Management of Heart Failure: Are We Shooting at the Right Target?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807228" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Determinants of the reduction in B-type natriuretic peptide after mitral valve replacement in patients with rheumatic mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600847" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparison of atrial and brain natriuretic peptide for the assessment of mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820049" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : NT pro B type natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936624" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28094130" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Acute systolic heart failure with normal admission BNP: clinical features and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040515" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A single BNP measurement in acute heart failure does not reflect the degree of congestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382416" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603309" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28829876" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682309" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539472" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447528" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097683" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
